Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about AMPK / energy sensing / metabolic regulation: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| PRKAA1 | participates_in | gene | 0.58 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| AMPK hypersensitivity in astrocytes creates enhanced mitocho | 0.791 | neurodegeneration | Mitochondrial transfer between astrocyte |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.791
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Sirtuin Pathway Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neuro | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Animal Model Comparison for Neurodegenerative Disease Therapeutics | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Responder Prediction Study — Precision Medicine for Neur | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Peroxisome Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Metabolic Pathway-Targeted Therapy in ALS | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614] | Han QQ, Shen SY, Liang LF, Chen XR, Yu J | Brain Behav Immun | 2024 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK [PMID:31693892] | Wang Y, An H, Liu T, Qin C, Sesaki H, Gu | Cell Rep | 2019 | 1 |
| AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking Sy [PMID:30057310] | Song X, Zhu S, Chen P, Hou W, Wen Q, Liu | Curr Biol | 2018 | 1 |
| Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuro [PMID:26121488] | Hang L, Thundyil J, Lim KL | Ann N Y Acad Sci | 2015 | 1 |
| Single-cell transcriptome analysis reveals a cellular immune response in common [PMID:41692207] | Shi X, Ji G, Liu D, Zhao T, Tian S, Li S | International journal of biolo | 2026 | 0 |
| AMPKα1 Deficiency in Macrophages Impairs Tendon Regeneration and Tendon Stem Cel [PMID:41694579] | Zhu L, Wang Y, Shi X, Yu M, Cai X, Chen | International journal of biolo | 2026 | 0 |
| Farrerol ameliorates hepatic insulin resistance via AMPKα1/mTOR/SREBP-1 pathway: [PMID:41702183] | Li Y, Feng X, Zheng L | Tissue & cell | 2026 | 0 |
| Integration proteomics analysis to identify AMPK as key target pathways of TCM f [PMID:41788172] | Chen YJ, Ning DS, Wang CC, Zhao HW, Wang | Journal of traditional and com | 2026 | 0 |
| Baicalein limits subchondral bone lesions via AMPKα/BECN1 activation in osteoart [PMID:41791307] | Zhai Y, Zhou P, Dan L, Ma M, Liu B, Zhan | International immunopharmacolo | 2026 | 0 |
| Integrative SMR prioritizes oxidative stress-related regulatory genes for Alzhei [PMID:41844011] | Wu L, Dong YT, Mu X, Luo X, Chen ZJ | The journal of prevention of A | 2026 | 0 |
| The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974] | Dai L, Wang J, Meng L, Zhang X, Xiao T, | PLoS biology | 2025 | 0 |
| Assessment of the Spatial Distribution of Moisture Content in Granular Material [PMID:31234567] | ["Porzuczek J"] | Sensors (Basel, Switzerland) | 2024 | 0 |
| Retracted: Ginsenoside Rg1 Ameliorates Acute Renal Ischemia/Reperfusion Injury v [PMID:38234567] | ["Longevity O"] | Oxidative medicine and cellula | 2024 | 0 |
| Optimal Control with RdCVFL for Degenerating Photoreceptors. [PMID:38345678] | ["Wifvat K", "Camacho E", "Kawski M", "L | Bulletin of mathematical biolo | 2024 | 0 |
| An ESIPT + AIE based dual-response fluorescent probe for continuous detection of [PMID:38901234] | ["Zhao J", "Dai C", "Gu B", "Wei M"] | Spectrochimica acta. Part A, M | 2024 | 0 |
| Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1 [PMID:38953310] | Choi EJ, Oh HT, Lee SH, Zhang CS, Li M, | Autophagy | 2024 | 0 |
| Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-80 [PMID:39309511] | Li B, Xiao Q, Zhao H, Zhang J, Yang C, Z | Acta pharmaceutica Sinica. B | 2024 | 0 |
| Protective and Detoxifying Effects of Resveratrol on Zearalenone-Mediated Toxici [PMID:39456789] | ["Lv Q", "Xu W", "Yang F", "Li J", "Wei | International journal of molec | 2024 | 0 |
| A vision-based real-time traffic flow monitoring system for road intersections. [PMID:36789012] | ["Azimjonov J", "\u00d6zmen A", "Varan M | Multimedia tools and applicati | 2023 | 0 |
Multi-agent debates referencing this entity